PDUFA: Thoughts from PhRMA CEO John Castellani

PDUFA: Thoughts from PhRMA CEO John Castellani

05.23.12 | By Kate Connors

Prescription Drug User Fee ActThis year's reauthorization of the Prescription Drug User Fee Act is a top priority for PhRMA and for our member companies, who recognize the critical importance of providing FDA with the resources it needs to do its incredibly essential job.

Yesterday, PhRMA President and CEO John Castellani posted his thoughts on PDUFA reauthorization on the National Journal's Health Care Experts Blog.

The blog editors quote Rep. Henry Waxman as "one of many members who commended his colleagues for their ability to collaborate and compromise: 'Consideration of this bill should be a model for legislative action,' he said."

The question NJHCEB editors ask: "The 'UFA' legislation, as it's known, is nearly identical on the House and Senate sides, has passed through markups with nary a complaint, and looks set to pass months before the programs it reauthorizes are set to expire at the end of September. In a session marked by so much partisan rancor, why are the UFA bills different? What can Congress learn from this process?"

In response, Castellani wrote: "Ensuring that patients have timely access to the latest therapies isn't a partisan goal, it's a personal goal and a public health goal. Hence the bipartisan support for this critical legislation."

Read his entire column, as well as a response from Senator Michael Bennet, here.

More On PhRMA — powered by PhRMApedia


Cost in Context